Ribon Therapeutics to Present at Upcoming Scientific Conferences
Cambridge, MA – Jan. 24, 2020 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, today announced it will be presenting at two upcoming scientific conferences.
PARP & DDR Inhibitors Summit
Jan. 28-30, 2020
Location: Revere Hotel, Boston, MA
- Presentation: Not all PARPs are Alike: Exploring the Therapeutic Potential of PARPi Beyond PARP1 Inhibitors
- Speaker: Heike Keilhack, SVP of Biological Sciences
- Time: 10am ET, Wednesday, Jan. 29
SLAS 2020 International Conference and Exhibition
Jan. 25-29, 2020
Location: San Diego Convention Center, San Diego, CA
- Podium presentation: A Bespoke Screening Platform to Study mono(ADP-ribosylation)
- Speaker: Tim Wigle, Director, Molecular Discovery Group
- Time: 2:30pm PT, Wednesday, Jan. 29
- Poster presentation: Development of Novel Biochemical Assays for the Screening of MonoPARP Enzymes
- Speaker: Dave Church, Sr. Research Associate, Molecular Discovery Group
- Time: 5:00pm PT, Tuesday, Jan. 28
About Ribon Therapeutics
Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts.
Media Contact:
Cory Tromblee
Scient PR
[email protected]